Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 51 for “"NMIBC"”.
-
Germline prognostic markers for urinary bladder cancer
… However, non-muscle invasive bladder cancer (NMIBC) cases show high recurrence and progression rates and inconsistencies within the NMIBC risk group, resulting in a substantial burden on patients and health systems. The evidence for genetic risk factors having a role in NMIBC susceptibility …
-
Prognostic Features of Non-Muscle-Invasive Bladder Cancer: Grade, Molecular Subtype and Tumour Immune Microenvironment
… stage, non-muscle-invasive bladder cancers (NMIBCs) have hindered implementation of subtyping in routine clinical practice. Furthermore, the current grading classification for NMIBC includes a low-risk category known as PUNLMP and has been understudied with respect to molecular subtypes that …
-
Quality of life in newly diagnosed bladder cancer patients
… survival for non-muscle invasive bladder cancer (NMIBC) is high, and these patients will need to live with acceptable HRQoL for many years. I investigated HRQoL in 1258 muscle invasive bladder cancer (MIBC) and NMIBC patients participating in the Bladder Cancer Prognosis Programme. Although I …
-
An Epidemiology Study of Prognositic Factors for Non-Muscle Invasive Bladder Cancer
… early as non-muscle-invasive bladder cancer (NMIBC), of which 50-70% cases will experience recurrence and 10-30% will further develop to muscle-invasive stages with poor prognosis. Such an extraordinarily high recurrence/progression rate makes bladder cancer the most expensive cancer to treat …
-
Effect of Hypoxia on the Expression of Immune Checkpoint Molecules in Non-Muscle Invasive Bladder Cancer
… with non-muscle invasive bladder cancer (NMIBC). Hypoxia within the tumor microenvironment (TME) is a driver of immune evasion and is a potential prognostic marker for NMIBC. One key mechanism of immune evasion involves the upregulation of immune checkpoint proteins (ICPs) on tumour cells, …
-
Follow-Up of superficial urothelial carcinoma with non-invasive diagnostic tools. literature review /
… (UC), or non-muscle-invasive bladder cancer (NMIBC), represents the predominant form of bladder cancer which is associated with a significant risk of recurrence and progression. Conventional surveillance techniques, such as cystoscopy and cytology, continue to be the benchmark in follow up in …
-
Using self-associating supramolecular amphiphiles as a novel enhancer of anticancer drug delivery to treat non-muscle invasive bladder cancer
Non-muscle invasive bladder cancer (NMIBC) represents up to 70% of the 10,500 new bladder cancer diagnoses made each year in the UK. High recurrence rates are the most significant unmet clinical need of NMIBC, with up to 75% of patients predicted to have their cancer recur within five years …
-
Investigating Relationships Between Quantitative Nuclear Grading Features and Prognosis in Non-Muscle Invasive Bladder Cancer
… grading in non-muscle invasive bladder cancer (NMIBC) aims to predict how quickly the cancer will grow and spread, guiding disease management through its role in risk scoring. However, the qualitative nature of the current NMIBC grading system limits the ability to optimize its prognostic value, …
-
Investigating Sexual Dimorphism in Murine Bladders and Plasmacytoid Dendritic Cell Response to BCG and STING Pathway Activation
… mainstay for non-muscle invasive bladder cancer (NMIBC) treatment. Unfortunately, over 50% of patients do not respond optimally and exhibit recurrence or progression to an invasive disease. Recent findings have demonstrated sexual dimorphism in the tumor immune microenvironment of NMIBC and …
-
COMBINING BCG IMMUNOTHERAPY WITH STING PATHWAY ACTIVATION TO INDUCE TERTIARY LYMPHOID STRUCTURES IN THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER
… high-risk non-muscle invasive bladder cancer (NMIBC) is best treated with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. BCG is the live-attenuated form of Mycobacterium bovis and is utilized in an adjuvant setting to recruit immune cells and potentiate anti-tumor immunity. Like …
-
En-Block resection of bladder tumor. literature review and case report /
… treatment of non-muscle invasive bladder cancer (NMIBC) has long been the transurethral resection of bladder tumors (TURBT). This method is practical and feasible. However, there are also some concerns regarding this resection method. Conventional TURBT does not respect standard oncological …
-
Visible Light Controlled Combination Strategy to Treat Non-Muscle Invasive Bladder Cancer
… with non-muscle invasive bladder cancer (NMIBC). During this stage, the tumor is superficial or has only spread to the inner lining of the bladder without involving the surrounding muscle layer. It is possible to save a patient's bladder or life if a tumor is controlled at this stage to …
-
Age-associated mucosal and systemic immunomodulation by Bacillus Calmette-Guérin immunotherapy in Non-Muscle Invasive Bladder Cancer
Non-muscle invasive bladder cancer (NMIBC) constitutes approximately 75% of bladder cancer cases. Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy remains the standard of care for high-risk NMIBC, however clinical outcomes remain suboptimal. This limited efficacy is largely attributed to …
-
Die Bedeutung von micro-RNA-9, -21, -29c, -145, -200c, -205 und -221 für die Genese und Progression des Urothelkarzinoms der Harnblase – miR-29c als Progressionsmarker im nicht-muskelinvasiven Urothelkarzinom
… ein archiviertes Gewebekollektiv, bestehend aus NMIBC, MIBC und benignem Referenzmaterial verwendet und die mittels RT-PCR ermittelte miR-Expression mit klinischen Parametern sowie Follow-up-Daten korreliert. Letztlich konnte für unterschiedliche micro-RNAs ein Einfluss auf das Urothelkarzinom im …
-
Effect of Systemic Versus Localized Bacillus Calmette-Guérin Immunotherapy on Bladder Cancer Progression: Novel Role for Trained Immunity
… high-risk non-muscle invasive bladder cancer (NMIBC) involves intravesical immunotherapy with Bacillus Calmette Guérin (BCG). Unfortunately, most patients do not respond fully to this therapy, and our understanding of the immunotherapeutic effect of BCG is incomplete. The tumor immune …
-
Creating new quantitative features to predict recurrence risk in non-muscle invasive bladder cancer
Background: Non-muscle invasive bladder cancer (NMIBC) grading follows two systems: WHO 1973 (Grade 1, 2, 3 [G1, G2, G3]) and WHO 2004 (Papillary Urothelial Neoplasm of Low Malignant Potential [PUNLMP], Low Grade [LG], High Grade [HG]). WHO 1973 lacks clear criteria, causing disagreements among …
-
Molecular evaluation of early bladder cancer to improve clinical decision making
… clinically divided into non-muscle invasive BC (NMIBC) and muscle-invasive BC (MIBC). Low-grade NMIBCs usually undergo surveillance for many years with recurrent cystoscopies and TURBTs, while high-grade tumours are treated with BCG (Bacillus Calmette–Guérin) instillations in addition to …
-
A functional role of DOT1L in luminal muscle invasive bladder cancer
… into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). While NMIBC is a low-grade tumor, MIBC is a high-grade tumor that tends to metastasize. MIBC tumors are further grouped into different molecular subtypes defined by specific gene expression …
-
Investigating the impact of inflammasomes in bladder cancer
… subtypes. Non-muscle invasive bladder cancer (NMIBC) is defined as BC that is confined to the urothelium and lamina propria, and accounts for 70% of BC diagnoses. Muscle-invasive bladder cancer (MIBC) has invaded beyond the lamina propria and into the detrusor smooth muscle Although the …
-
Viscoelastic properties of the bladder and design of a surgical instrument for the removal of bladder tumours
… for removing non-muscle invasive bladder cancer (NMIBC) is tumour re-implantation. An add-on instrument was designed, manufactured and tested to attempt to stop the travel of tumourous cells which could then re-implant. A prototype of the device was manufactured using the shape memory metal nickel …
Page 1 of 3